Traumatic Brain Injury

Traumatic Brain Injury Leads to Neurodegeneration It is well-known that Traumatic Brain Injury (TBI) leads to development of Parkinson’s or Alzheimer’s Disease Related Pathology. The natural association between TBI and neurodegenerative disorders has been historically related to boxing. However, american football players, wrestlers, rugby players, military personnel, etc., any person with violent encounters suffering repetitive…

Stem Cells

A few weeks ago, a “Current Perspective of Stem Cell Therapy in Neurodegenerative and Metabolic Diseases” was published in the Molecular Neurobiology journal [1], New, exciting advances looking for a cure for neurodegenerative diseases by using stem cells, are summarized in that review. A stem cell is one with the ability to continuously divide and differentiate into…

Multiple Sclerosis Vaccines

Multiple Sclerosis (MS) is a chronic, typically progressive disease involving damage to the sheaths of nerve cells in the brain and spinal cord.  It is the most common inflammatory, demyelinating, and neurodegenerative disorder of the central nervous system (CNS). The symptoms of this unpredictable, disabling disease in many cases, may include numbness, impairment of speech…

The Price to Pay

Mov Disord. 2013 Mar;28(3):319-26. doi: 10.1002/mds.25328. Epub 2013 Feb 12. An economic model of Parkinson’s disease: implications for slowing progression in the United States. Johnson SJ1, Diener MD, Kaltenboeck A, Birnbaum HG, Siderowf AD. Author information Abstract Multiple studies describe progression, dementia rates, direct and indirect costs, and health utility by Hoehn and Yahr (H&Y)…

Vaccines

Rinsho Shinkeigaku. 2009 Nov;49(11):848-50. [Vaccination therapy for Alzheimer’s disease]. [Article in Japanese] Tabira T1. Author information Abstract Since AN-1792 vaccine induced autoimmune encephalitis, several pharmaceutical companies are now concentrated in developing antibody therapy in Alzheimer’s disease (AD). Each antibody has own characteristics. Thus, it is unpredictable at present which antibody is the most beneficial until…

Is There a Role for Vitamins?

Int J Mol Sci. 2016 Oct 26;17(11). pii: E1785. The Impact of Vitamin E and Other Fat-Soluble Vitamins on Alzheimer´s Disease. Grimm MO1,2,3, Mett J4, Hartmann T5,6,7. Author information Abstract Alzheimer’s disease (AD) is the most common cause of dementia in the elderly population, currently affecting 46 million people worldwide. Histopathologically, the disease is characterized…

Examining the Risk Factors

Front Aging Neurosci. 2016 Oct 4;8:232. eCollection 2016. Triad of Risk for Late Onset Alzheimer’s: Mitochondrial Haplotype, APOE Genotype and Chromosomal Sex. Wang Y1, Brinton RD2. Author information Abstract Brain is the most energetically demanding organ of the body, and is thus vulnerable to even modest decline in ATP generation. Multiple neurodegenerative diseases are associated…

The Lipids Issue

Cell Tissue Res. 2016 Jul 23. [Epub ahead of print] Mitochondrial lipids in neurodegeneration. Aufschnaiter A1, Kohler V1, Diessl J2, Peselj C2, Carmona-Gutierrez D1, Keller W1, Büttner S3,4. Author information Abstract Mitochondrial dysfunction is a common feature of many neurodegenerative diseases, including proteinopathies such as Alzheimer’s or Parkinson’s disease, which are characterized by the deposition…

Sex hormones

Adv Mater. 2016 Aug;28(30):6345-52. doi: 10.1002/adma.201600554. Epub 2016 May 11. Traceable Nanoparticle Delivery of Small Interfering RNA and Retinoic Acid with Temporally Release Ability to Control Neural Stem Cell Differentiation for Alzheimer’s Disease Therapy. Zhang R1,2, Li Y1, Hu B1, Lu Z1,3, Zhang J2, Zhang X1. Author information Abstract Nanoparticles that can efficiently control the…

Cannabinoids

Glia. 2017 Jan;65(1):122-137. doi: 10.1002/glia.23080. Epub 2016 Oct 19. Cannabinoids prevent the amyloid β-induced activation of astroglial hemichannels: A neuroprotective mechanism. Gajardo-Gómez R1, Labra VC1, Maturana CJ1, Shoji KF2, Santibañez CA1, Sáez JC2, Giaume C3, Orellana JA1. Author information Abstract The mechanisms involved in Alzheimer’s disease are not completely understood and how astrocytes and their…

Alzheimer, Perspectives

Oncotarget. 2016 Jun 28;7(26):38999-39016. doi: 10.18632/oncotarget.9175. Alzheimer disease research in the 21st century: past and current failures, new perspectives and funding priorities. Pistollato F1, Ohayon EL2, Lam A1,2, Langley GR3, Novak TJ4, Pamies D5, Perry G6, Trushina E7, Williams RS8, Roher AE9,10, Hartung T5, Harnad S11, Barnard N1, Morris MC12, Lai MC1, Merkley R1, Chandrasekera…

Alzheimer, FDA-approved drugs

Expert Rev Clin Pharmacol. 2014 Mar;7(2):161-5. doi: 10.1586/17512433.2014.884923. Epub 2014 Feb 6. Repackaging FDA-approved drugs for degenerative diseases: promises and challenges. Cummings JL1, Zhong K. Author information Abstract Repurposing refers to the therapeutic use of a drug or drug candidate for a disease other than that for which it was originally intended. Repurposing is attractive…